Clinical application of CyberKnife for high-risk central nervous system tumors: A clinical trial report of 60 cases

  • Authors:
    • Xin Wang
    • Yuan-Yuan Wang
    • Peng Jiang
    • Jian-Jun Ma
    • Zhen Qu
    • Han-Chen Liu
    • Shan-Shan Wang
    • Yi-Shan Wang
  • View Affiliations

  • Published online on: September 23, 2011     https://doi.org/10.3892/etm.2011.356
  • Pages: 105-108
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The objective of the present study was to evaluate the application potential of CyberKnife for high-risk tumors of the central nervous system and to analyze the effectiveness of CyberKnife in relation to dose recovery and gain division (times). A total of Eighty-one targeted areas from 139 central nervous tumor lesions in 60 patients were treated with I-VI ranged CyberKnife for 1 week. Following CyberKnife treatment, imaging tests revealed a decrease in tumor volume, reduction of central nervous system symptoms and an increase in the life quality of patients. The advantages of CyberKnife include non-invasiveness, individualized treatment, flexibility, high accuracy and rapid treatment. CyberKnife produces slight damage and a favorable therapeutic effect and expands our concepts concerning precise radiotherapy for tumors. It is an indispensable method for personalized tumor treatment.

Introduction

Patients with high-risk central nervous system tumors commonly refuse surgery or receive partial resection due to the difficulty and risk of surgery, and the rapid recurrence of tumors (13). Palliative treatment is often applied because of the inability to perform surgery, regular radiation or chemotherapy due to the invasion of central organs with important functions by tumor infiltration and multiple metastases (46). Direct involvement or activation of local nociceptors as well as adjacent nerves, vessels, central nervous tissue as suppressed by tumors may lead to paralysis or paraplegia accompanied by pain and tumor compression complex (79). Using CyberKnife to control or reduce local lesions, we attempted to improve the internal environment, to reduce adverse reactions, to control tumor progression and to alleviate clinical symptoms.

Materials and methods

Subjects

A total of 139 central nervous system tumor lesions in 60 patients who received palliative treatment at the Center for Non-Traumatic Treatment and Diagnosis of Tumor, Binzhou Medical College Affiliated with the PLA 107th Hospital, from October 2010 to May 2011, were selected for the study according to the following standards. i) Diagnosis of tumors was confirmed by pathology or imaging tests, such as CT and MRI, and were ranked as stages III–IV according to the WHO clinical staging system. ii) Patients had an ECOG Performance status 2–4. iii) Patients exhibited crudescence following surgery, invasion of central organs with vital functions, infiltration of lymph and neurons or multiple metastases and had no indications for surgery or were unable to undergo standard chemical or radiotherapy. iv) Patients provided informed consent. The exclusion criteria included i) associated Tb, undetermined diagnosis, early stage disease with surgical indications; ii) intractable increased intracranial pressure; iii) recent repeated radiotherapy or suspected radiotherapy complications.

A total of 38 males and 22 females, 6–63 years of age, with an average age of 50 years, were enrolled. There were 81 targeted areas from 139 lesions including 9 gliomas, 23 brain metastases, 8 meningiomas, 11 pituitary tumors, 8 intramedullary spinal cord tumors and 1 spinal meningioma. Between 1 and 24 lesions were noted in each patient, 1–6 lesions were planned to be targeted, and 31 cases suffered from brain swelling.

Methods

CT slices (1.25-mm) were performed after hospitalization. IMR, PET-CT or DSA image fusion was conducted when necessary to determine the target areas. Centrum or skull 6D tracking outlined target CTV. Treatment plans and treatment doses were determined according to the number of tumor lesions and tumor size. Treatment was carried out 1–6 times, and complete treatment spanned 1 week.

Evaluation

Stereotactic radiowave surgery platform specifications: CyberKnife System (Accuray Group Co., Ltd., USA). The output dose rate was 400–600 cGy. The US FDA granted market access for systemic treatment as certified in August 2001. Tumor dose coverage was 85–95%. For patients with small and single-tumor lesions, the general dose was 1–3 F; for those with large and multiple tumor lesions the general dose was 4–6 F. The tumor dose DT was 18–60 Gy, with a single dose of 4–18 Gy.

Criteria

Evaluation: i) imaging examination, shrinkage; ii) RIA and endocrine hormone detection, decrease or recover; iii) Zubrod-ECOG-WHO (ZPS) (10) scale 1–4: 0, normal activity; 1, some symptoms but still almost fully ambulatory; 2, <0% of daytime spent in bed; 3, >50% of daytime spent in bed; 4, completely bedridden; 5, deceased.

WHO objective criteria of curative effect (11)

CR, complete remission with symptoms and physical signs totally disappeared for 4 weeks; PR, partial remission with tumor volume shrinkage >50% for at least 4 weeks; NC, no significant change observable for at least 4 weeks with a tumor volume increase of ≤25% or shrinkage ≥50%; PD, progressive disease with new lesions appearing or the original lesion increasing >25% in size. The total effective rate was calculated with the following equation: (CR + PR)/total cases × 100%.

Statistical analysis

All values are expressed as the means ± standard deviation (SD). Differences were evaluated using Statistical Package for Social Science 13.0 (SPSS13.0). Statistical analysis was performed using the two-sided Student’s t-test. Differences were considered statistically significant at the level of p<0.05.

Results

Case statistics

A total of 63 cases were assessed. Three cases were excluded; 2 cases could not follow the study instructions because of age and 1 case experienced financial problems. A total of 60 cases were involved in the final analysis.

Imaging tests

High-risk patients with at least one of the following conditions (tumor recurrence after surgery, multiple metastases, disease uncontrollable by either radiation or chemotherapy, invalid conservative therapy, or diagnosis at an advanced stage) exhibited significant shrinkage or disappearance of lesions as confirmed by imaging compared to 120 advanced patients who received only conservative therapy by conformal radiation therapy.

RIA monitoring and endocrine hormone condition

Compared to the control group, 5 of 24 patients with increased tumor markers or endocrine hormone became negative, 10 cases were degraded to varying degrees, 6 cases had no obvious changes and 3 cases increased following CyberKnife treatment.

ZPS scores were improved to various degrees in all the patients after treatment, accompanied by alleviation or disappearance of tumor suppression syndrome and pain syndrome.

Objective effect assessment

Patients with advanced cancer who received repeated treatment also showed a high rate of alleviation of symptoms after CyberKnife treatment. The brain stem invaded by intracranial multiple metastases (24 lesions) caused severe central nervous system suppression syndrome, and the treatment plans were divided into six parts with at most one target for six tumor lesions. The patients were able to take care of themselves after completion of treatment in 19 days (Fig. 1). Patients with meningiomas (3.4×3.0×2.7 cm3) who refused surgery due to the high risk by severe medulla oblongata placeholder successfully accomplished therapeutic treatment utilizing CyberKnife (Fig. 2). Another case with chest intramedullary hemangiomas (reaching a length of 14 cm) who was paralyzed in bed and could not care of himself recovered after CyberKnife treatment and was able to walk following 4 administrations of CyberKnife treatment (Fig. 3).

Discussion

Palliative treatment is the major treatment for patients suffering from central nervous system tumors, particularly brain glioma, metastatic tumors and spinal cord tumors (1218). Surgery or conventional radiotherapy is unable to provide a complete cure due to the late diagnosis of these advanced tumors, the rapid growth of the tumors, and compression or infiltration of important organs (13,1922). CyberKnife is a flexible method having the advantage of high accuracy, timely tracking, shorter treatment times, a high-dose, short treatment course, easy patient access to treatment, improved local cure rate and favorable results (22,23). Statistical results from 60 patients with advanced complex tumors and from 120 patients receiving advanced palliative radiotherapy showed that, after treatment, in some cases CyberKnife even achieved complete remission; the effective rate was 71.7%, suggesting an effective noninvasive treatment for cancer.

CyberKnife technology facilitates cancer treatment and improves the local control rate, especially in high-risk patients (2427). Most patients receiving CyberKnife do not require hospitalization (2831), treatment time is short (32,33), and no toxic side effects occur (3436). We believe that treatment time, frequency and dose should be based on the number of tumors, size, severity of the disease, repeated during the length of the treatment time. This means that treatment should reflect the individual needs and not blindly pursue a rapid treatment. CyberKnife can be carried out without hospitalization or early discharge. At the end of treatment, normal routine blood examination should be carried out. However, after 1–2 weeks of treatment, if grain dump, brain edema, intracranial pressure and orthostatic hypotension occurs, it is necessary for the patients to be hospitalized for observation, consolidation effect, thus they can be excluded from CyberKnife ‘surgery’ which may cause potential adverse reactions (37).

CyberKnife also incorporates the merits of the Gamma (X) knife while overcoming its shortcomings, such as the need for tumor shape and oversized target areas (38). It works effectively in the cancer therapy of central nervous system tumors. CyberKnife could interface with a variety of imaging examinations, including CT, MRI, PET-CT and DSA, and obtain three-dimensional image to offer the most direct evidence for gross targeted region delineation (39). CyberKnife requires more strict target delineation than ordinary radiotherapy, but not as traditional as conformal radiation therapy (40). Careful forethought should be given due to the CyberKnife portrait of fewer but larger doses.

In conclusion, using CyberKnife therapy, the quality of life of patients with high-risk central nervous system cancer markedly improves, symptoms are rapidly alleviated and patients need not undergo surgery (41). CyberKnife is a new effective therapeutic method for treating advanced high-risk central nervous system cancers.

Acknowledgements

This study was supported, in part, by grants from the National Special Issue of the Ministry of Health of China (no. 2009BX042), the Foundation of Military Scientific and Technological Issue (no. 06G034), and the Project of Key Program of Jinan Military Region (no. 02Z07).

References

1. 

J ThariatS BolleY DemizuNew techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions, Improved effectiveness and safety? Impact on survival?Anticancer Drugs213201021051993

2. 

X QiaoO TullgrenI LaxThe role of radiotherapy in treatment of stage I non-small cell lung cancerLung Cancer41111200310.1016/S0169-5002(03)00152-112826306

3. 

RC McGarryL PapiezM WilliamsStereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I studyInt J Radiat Oncol Biol Phys6310101015200510.1016/j.ijrobp.2005.03.07316115740

4. 

J WulfU HaedingerU OppitzStereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patientsInt J Radiat Oncol Biol Phys60186196200410.1016/j.ijrobp.2004.02.06015337555

5. 

H YamazakiH ShiomiT TsubokuraQuantitative assessment of inter-observer variability in target volume delineation on stereotactic radiotherapy treatment for pituitary adenoma and mentingioma optic tractRadiat Oncol6102011

6. 

CP HasneyRG SwantonPL FriendlanderCyberKnife stereotactic radiosurgery for recurrent squamous cell carcinoma of the head and neck following salvage surgery with close or positive marginsLaryngoscope4152201010.1002/lary.2161621225750

7. 

YS WangQW WangXF JiaThermal dose effect of regional radiofrequency hyperthermia on metaphase and advanced stage tumorJ Clin Rehab Tissue Engineering Res11901190152007

8. 

S DewasC Dewas-VautraversV ServentResults and special considerations when treating elderly patients with CyberKnife: a review of 345 casesCrit Rev Oncol Hematol7617201021146423

9. 

Y XieD DjajaputraCR KingIntrafractional motion of the prostate during hypofractionated radiotherapyInt J Radiat Oncol Biol Phys72236246200810.1016/j.ijrobp.2008.04.05118722274

10. 

F UngerK DominikusK Haselsberger[Stereotactic radio-surgery and fractionated stereotactic radiotherapy of acoustic neuromas.]HNO5931372011(In German).

11. 

S SharmaJ OttJ WilliamsDose calculation accuracy of the Monte Carlo Algorithm for CyberKnife compared with other commercially available dose calculation algorithmsMed Dosim3514201021144731

12. 

YS WangXD XuQW WangClinical research of partial IMCRT treated malignant ascites combined with Chinese medicine RFChin Med Front1885872007

13. 

VA MarcialTF PajakS KramerRadiation Therapy Oncology Group (RTOG) studies in head and neck cancerSem Oncol15396019883278390

14. 

BA Jereczed-FossaG BeltramoL FariselliRobotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancerInt J Radiat Oncol Biol Phys7919201121277113

15. 

JW DegenGJ GagnonJM VoyadzisCyberKnife stereotactic radiosurgical treatment of spinal tumors for pain control and quality of lifeJ Neurosurg Spine2540549200510.3171/spi.2005.2.5.054015945428

16. 

A SchweikardH ShiomiJ AdlerRespiration tracking in radiosurgeryMed Phys3127382741200410.1118/1.1774132

17. 

BT CollinsK EricksonCA ReichnerRadical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumorsRadiat Oncol239200710.1186/1748-717X-2-3917953752

18. 

C ReichnerB CollinsG GagnonThe placement of gold fiducials for CyberKnife stereotactic radiosurgery using a modified transbronchial needle aspiration techniqueJ Bronchol12193195200510.1097/01.lab.0000186345.85025.41

19. 

P TherasseSG ArbuckEA EisenhauerNew guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst92205216200010.1093/jnci/92.3.20510655437

20. 

L PapiezR TimmermanC DesRosiersExtracranial stereotactic radioablation: physical principlesActa Oncol42882894200310.1080/0284186031001349014968949

21. 

JR SimpsonME FrancisR Perez-TamayoPalliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trialInt J Radiat Oncol Biol Phys11751758198510.1016/0360-3016(85)90307-42579938

22. 

KW RohJS JangMS KimFractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancerInt J Radiat Oncol Biol Phys7413481355200910.1016/j.ijrobp.2008.10.013

23. 

HJ ChenSW LeungCY SuLinear accelerator based radiosurgery as a salvage treatment for skull base and intracranial invasion of recurrent nasopharyngeal carcinomaJ Clin Oncol24255258200110.1097/00000421-200106000-0000911404496

24. 

SC SharmaClinical implications of adopting Monte Carlo treatment planning for CyberKnifeJ Appl Clin Med Phys1170175201020160699

25. 

WT BrownX WuF FayadApplication of robotic stereotactic radiotherapy to peripheral stage I nonsmall cell lung cancer with curative intentClin Oncol21623631200910.1016/j.clon.2009.06.00619682875

26. 

WT BrownX WuBC WenEarly results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumorsComput Aided Surg12253261200710.3109/1092908070168475417957532

27. 

LE ErrettJ WilsonRC ChiuWedge resection as an alternative procedure for peripheral bronchogenic carcinoma in poor-risk patientsJ Thorac Cardiovasc Surg9065666119853932783

28. 

BK ChangRD TimmermanStereotactic body radiation therapy: a comprehensive reviewAm J Clin Oncol30637644200710.1097/COC.0b013e3180ca7cb118091059

29. 

W HaraBW LooDR GoffinetExcellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys71393400200810.1016/j.ijrobp.2007.10.02718164839

30. 

A VavassoriBA Jereczek-FossaG BeltramoImageguided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six casesTumori9671752010

31. 

BA Jereczek-FossaL FariselliG BeltramoLinac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancerRadiother Oncol931417200910.1016/j.radonc.2009.04.001

32. 

JF FowlerJS WelshSP HowardLoss of biological effect in prolonged fraction deliveryInt J Radiat Oncol Biol Phys159242249200410.1016/j.ijrobp.2004.01.00415093921

33. 

J ThariatG LiG AngellierCurrent indications and ongoing clinical trials with CyberKnife stereotactic radiotherapy in France in 2009Bull Cancer96853864200919736172

34. 

N Calcerrada Daz-SantosJA Blasco AmaroGA CardielThe safety and efficacy of robotic image-guided radiosurgery system treatment for intra- and extracranial lesions: a systematic review of the literatureRadiother Oncol892452532008

35. 

DB FullerJ NaitohC LeeVirtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observationsInt J Radiat Oncol Biol Phys7015881597200810.1016/j.ijrobp.2007.11.067

36. 

SC SharmaJT OttJB WilliamsD DickowCommissioning and acceptance testing of a CyberKnife linear acceleratorJ Appl Clin Med Phys82473200710.1120/jacmp.v8i3.247317712305

37. 

RD BucholzKA LaycockLE CuffCyberKnife stereotactic radiosurgery for intracranial neoplasms, with a focus on malignant tumorsTechnol Cancer Res Treat9541550201010.1177/15330346100090060221070076

38. 

CR KingJD BrooksH GillT PawlickiC CotrutzJC Presti JrStereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trialInt J Radiat Oncol Biol Phys7310431048200910.1016/j.ijrobp.2008.05.05918755555

39. 

B WowraA MuacevicJC TonnQuality of radiosurgery for single brain metastases with respect to treatment technology: a matched-pair analysisJ Neurooncol946977200910.1007/s11060-009-9802-y19184641

40. 

HU AhmedA IshaqE ZacharakisRectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapyBJU Int103321323200910.1111/j.1464-410X.2008.08026.x19021611

41. 

BO ChoiIB ChoiHS JangStereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysisBMC Cancer8351200810.1186/1471-2407-8-351

Related Articles

Journal Cover

January 2012
Volume 3 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang X, Wang Y, Jiang P, Ma J, Qu Z, Liu H, Wang S and Wang Y: Clinical application of CyberKnife for high-risk central nervous system tumors: A clinical trial report of 60 cases. Exp Ther Med 3: 105-108, 2012.
APA
Wang, X., Wang, Y., Jiang, P., Ma, J., Qu, Z., Liu, H. ... Wang, Y. (2012). Clinical application of CyberKnife for high-risk central nervous system tumors: A clinical trial report of 60 cases. Experimental and Therapeutic Medicine, 3, 105-108. https://doi.org/10.3892/etm.2011.356
MLA
Wang, X., Wang, Y., Jiang, P., Ma, J., Qu, Z., Liu, H., Wang, S., Wang, Y."Clinical application of CyberKnife for high-risk central nervous system tumors: A clinical trial report of 60 cases". Experimental and Therapeutic Medicine 3.1 (2012): 105-108.
Chicago
Wang, X., Wang, Y., Jiang, P., Ma, J., Qu, Z., Liu, H., Wang, S., Wang, Y."Clinical application of CyberKnife for high-risk central nervous system tumors: A clinical trial report of 60 cases". Experimental and Therapeutic Medicine 3, no. 1 (2012): 105-108. https://doi.org/10.3892/etm.2011.356